Toll Free : +1-800-792-5285 | (UK) : + 44-845-528-1300
Formats*: 
Author(s): HIV Drug Market Overview
Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016 - 2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS).
The major factors that boost the growth of the market include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the growth of the market.
HIV DRUG MARKET: SEGMENTATION
Segment Review:
The global HIV drugs market is segmented by medication class and geography. On the basis of medication class, the market is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors Among the medication class, the multi-class combination drugs hold the largest market share as it’s the most advanced technique used for the treatment of HIV infection. This is due to the increase in adoption of drugs from this medication class owing to their better results in the control of HIV & related coinfections and their ease in consumption & adherence.
TOP INVESTMENT POCKETS
Top Impacting Factors:
Increase in number of HIV infected patients worldwide
According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS-related illness in the same year. The world has very high prevalence of people living with HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection. In the emerging nations such sub-Saharan Africa, countries with low income do not have sufficient funds to buy high price drugs leading to increase in the population living with HIV.
Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
The federal government agencies, and various associations across the globe have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care. For instance, in 2010 the U.S. government launched the National HIV/AIDS Strategy, a five year initiative with various strategic goals, which include the plan to reduce incidence of HIV infections and to increase the access to treatment. This National HIV/AIDS Strategy was further extended by the government to 2020 in July 2015.
The increase in awareness among people regarding diagnosis and management of the diseases due to various such initiatives increase the treatment rate and thus, this factor acts as an important driver for the growth of the HIV drug market.
Introduction of generic drugs of HIV drugs
Generic drugs are the revised copy of the branded drugs with slight modifications in the ingredients and are launched in the market after the patent expiry of the branded drugs. Companies such as Mylan Pharmaceuticals Inc., Hetero Labs Ltd., and other such companies majorly work on generic version of the HIV drugs, launching them at cheaper costs. Patent expiration of the blockbuster drugs helps introduce the generic version, which promotes generic drug pharmaceutical market growth. The adoption of generic HIV drugs is very high because they offer same treatment as branded drugs at a very lost cost and are highly preferred in low income regions such as Africa.
Stringent regulatory requirements for the approval and commercialization of HIV drugs
Each new HIV drug must go through the regulatory approval process and meet the standard requirements. This process is stringent and time-consuming. The commercialization and approval of these drugs is regulated by agencies such as CE and FDA. The manufacturer must compile a file for every pipeline drug to include information, such as AIP (Application Integrity Policy), its use, and risk assessment while filling the drug for approval. It is also involved in drug manufacturing and development to establish licensing. Similarly, EMA protects public and animal health by ensuring safety of HIV drugs for human. These stringent regulatory standards and guidelines obstruct the entrance of new players in the market.
Increasing number of products in the pipeline
Various pharma giants such as Boehringer Ingelheim, Gilead Sciences, Inc., Merck & Co., Inc. GSK, Roche, and others are continuously involved in the drug development to offer better drugs for the treatment of HIV for complete cure and to provide products with very less or no side effects. These companies also utilize various innovative technologies such as cell therapy and immunomodulation along with antivirals for the drug development. For instance, Bictegravir/F/TAF, F/TAF, GS-9620, which undergo clinical trials. This results in emergence of more effective treatments, showing quick results to treat HIV/AIDS. The launch of such innovative drugs in the market is expected to create the opportunities for HIV drugs market in the future.
Geographic Analysis:
The North American region accounted half of the share in the overall HIV drug market in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the North American HIV drug market is attributed to well-established healthcare system, higher diagnosis & treatment rate, government funding for R&D, and increase in the adoption of advanced treatment options from HIV infected population. However, Asia-Pacific & LAMEA are projected to grow at a faster CAGR during the forecast period.
HIV DRUG MARKET KEY BENEFITS:
The study provides an in-depth analysis of the HIV drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of the HIV drug market, by medication class, assists in the effective treatment of HIV/AIDS.
Key players are profiled and their strategies are analyzed thoroughly, which predicts the competitive outlook of the market.
HIV DRUG MARKET KEY SEGMENTS:
BY MEDICATION CLASS
Multi-Class Combination Drugs
Atripla
Complera
Prezcobix/Prezista
Stribild
Triumeq
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combivir
Emtriva
Epivir
Epzicom
Trizivir
Truvada
Viread
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Edurant
Intelence
Rescriptor
Sustiva
Viramune (Immediate Release)
Protease Inhibitors (PIs)
Aptivus
Crixivan
Kaletra
Lexiva
Norvir
Reyataz
Viracept
Fusion Inhibitors (FI)
Fuzeon
Entry Inhibitors
Selzentry
HIV Integrase Stand Transfer Inhibitors.
Isentress
Tivicay
MARKET BY GEOGRAPHY
North America
Europe
Asia-Pacific
LAMEA
THE KEY PLAYERS
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences, Inc.
Johnson & Johnson
Cipla Limited
LIST OF OTHER PLAYERS
(These players are not profiled in the report. The same will be included on request)
Daiichi Sankyo
Emcure
Hetero Drugs
Mylan
Direct : +1-503-894-6022